10.11
Iteos Therapeutics Inc (ITOS) 最新ニュース
iTeos Therapeutics accepts takeover bid from Concentra - The Pharma Letter
Concentra buys beleaguered iTeos at slight discount - PharmaLive
iTeos Therapeutics stock price target lowered to $10 at Leerink Partners - Investing.com Canada
What analysts say about iTeos Therapeutics Inc. stockMassive profits - jammulinksnews.com
Is iTeos Therapeutics Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
What drives iTeos Therapeutics Inc. stock priceFree Market Volatility Navigation Tips - jammulinksnews.com
iTeos Therapeutics (NASDAQ:ITOS) Given Outperform Rating at Wedbush - Defense World
Securities Law Risks in Biotech M&A: A Closer Look at iTeos Therapeutics' Proposed Acquisition - AInvest
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders - GlobeNewswire Inc.
Rowley Law PLLC Investigates iTeos Therapeutics Acquisition for Securities Law Violations - AInvest
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of ITeos Therapeutics, Inc. - 富途牛牛
Navigating ITOS Stock: ITeos Therapeutics Inc Journey - investchronicle.com
iTeos Therapeutics To Be Acquired by Concentra Biosciences - citybiz
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders - The Globe and Mail
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Concentra To Acquire ITeos - Nasdaq
The Strategic Rationale and Valuation Implications of Concentra Biosciences' Acquisition of iTeos Therapeutics - AInvest
iTeos Therapeutics, Inc. Enters Merger Agreement with Concentra Biosciences, LLC for $10.047 per Share Acquisition - Quiver Quantitative
iTeos Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire
iTeos Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - Informazione.it
What risks could impact iTeos Therapeutics Inc. stock performanceFree Stock Index Interpretation - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment - TipRanks
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Market Expert Consultation - Newser
What makes iTeos Therapeutics Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Query - Newser
GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab - TipRanks
iTeos Therapeutics (ITOS): An Example of Biotech Liquidations - MSN
iTeos Therapeutics Stock Jumps Following Operational Closure Announcement - MSN
(ITOS) Technical Data - news.stocktradersdaily.com
iTeos Therapeutics CEO Michel Detheux sells $1.59m in stock By Investing.com - Investing.com Nigeria
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Exchange Traded Concepts LLC Acquires 3,468 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics Holds Annual Stockholders Meeting - TipRanks
Stock Performance Spotlight: ITeos Therapeutics Inc (ITOS) Ends the Day at 10.10, Down by -0.69 - DWinneX
Learn to Evaluate (ITOS) using the Charts - news.stocktradersdaily.com
ITeos Therapeutics Insider Sold Shares Worth $1,048,264, According to a Recent SEC Filing - MarketScreener
大文字化:
|
ボリューム (24 時間):